IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable ...

Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies, today announced the completion of ...

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage ...

Elite freshman classes can come together a few different ways: volume of signees, positional fit, roster needs and projected ...

The U.S. Quality ESG Fund underperformed its benchmark this quarter despite resilient economic activity. Click here to read ...

YdX Labs has released its first spot trading product, starting with Solana, marking the first time U.S. users can access the ...

Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) is pleased to announce its 2026 budget with capital projects driving profitable growth within its core assets, along with a ...

From making real estate investing more attainable to developing 500-square-foot homes to fit in your backyard, here's why these rising stars of real estate are the ones to watch in 2025.

It’s the most wonderful time of the year … for letting someone else do the cooking! Here’s where to find your low-stress holiday dining plans, Orlando, whether you’re ...

Binance has added a new endpoint to its USDⓈ-M futures API — a move that points toward internal preparations for stock-linked ...

Biocytogen’s partner Ideaya Biosciences receives US FDA clearance to initiate phase 1 trial of IDE034, a potential first-in-class B7H3/ PTK7 bispecific ADC: Beijing Monday, Dece ...

Bohn, a teenager from Kronenwetter, outside of Wausau, died by suicide March 5, after hours of relentless blackmail threats ...